Expert Interview
A Second Look: Evaluating Immunic's IMU-856 for the Treatment of Celiac Disease with a gastroenterologist.
Ticker(s): IMUXInstitution: UCSF
- Associate Professor of Clinical Medicine in the Division of Gastroenterology at UCSF
- Treats 40 patient with celiac disease per year
- Clinical focus on inflammatory bowel disease, celiac disease, fecal microbiota transplants, eosinophilic esophagitis and other immune conditions affecting the gastrointestinal tract; Research focuses on the microbiome's role in IBD helping to facilitate clinical trials investigating microbial therapy for various gastrointestinal illnesses.
Can you explain the mechanism of action of IMU-856, especially its targeting of SIRT6 (Sirtuin 6), and how it differentiates from other treatments available for Celiac Disease?
Based on the data from the Phase 1b clinical trial, how does IMU-856's efficacy compare to other Celiac Disease treatments? Are there specific outcomes, like the protection of gut architecture and enhancement of nutrient absorption, that stand out in its effectiveness?
Given that IMU-856 aims to restore a healthy gut by renewal of the gut wall, how does it address the unmet medical needs in Celiac Disease therapy?
Added By: sara_adminFrom the data presented, how would you characterize the safety profile of IMU-856? Were there any significant adverse events or side effects that clinicians should be aware of?
The trial indicated positive biomarker responses. How significant are these findings, and what implications might they have for the broader Celiac Disease patient population?
With the company preparing for phase 2 clinical testing, what are your expectations for the global reception and potential adoption of IMU-856?
Added By: sara_adminGiven the unique construct of IMU-856 and its potential impact, how do you see the competitive landscape shaping up for IMU-856 in the Celiac Disease market? Are there any potential competitors or emerging treatments that might challenge its position?
Added By: sara_admin Should IMU-856 receive regulatory approvals, how do you envision it affecting Immunic, Inc.'s overall drug pipeline, especially considering their other developments like vidofludimus calcium (IMU-838)?
Given the ongoing medical advancements in Celiac Disease and the potential of small molecule therapies, where do you position IMU-856 in the broader treatment paradigm for Celiac Disease?
Considering the chronic nature of Celiac Disease, how transformative do you believe IMU-856 could be in changing the standard of care for Celiac Disease patients?
Added By: sara_adminWith IMU-856 being an orally available and systemically acting small molecule modulator, can you provide insights into the potential scalability and production capabilities for IMU-856?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
